RNA-based therapies, including RNA molecules as drugs and RNA-targeted small
molecules, offer unique opportunities to expand the range of therapeutic targets. Various …

Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of
people around the globe and are a major public health burden. Most contemporary …

Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

As dyslipidemias remain one of the main risk factors for developing cardiovascular disease,
the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of …

Abstract Inclisiran (Leqvio®; Novartis) is a first-in-class, cholesterol-lowering small
interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates …

Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of
atherosclerotic cardiovascular disease. Statins have been the gold standard for managing …

Purpose of review Based on the recent data of the DA VINCI study, it is clear that, besides
utilization of statins, there is a need to increase non-statin lipid lowering approaches to …